Immunisation program

The following information provides health professionals with current immunisation information, updates and resources and links to vaccination education courses.

The immunisation schedules provide information on current National Immunisation Program (NIP) vaccination advice for children, adolescents and adults.

Download the current schedule using the links below.

Save the schedules to your desktop for access to quick links for further information. Replace all immunisation schedules when they are updated.

Access the Australian Immunisation Handbook for current vaccine advice.

National RSV Maternal and Infant Protection Program

Respiratory Syncytial Virus RSV is a highly infectious virus that is the most common cause of respiratory infections in children, with almost all children being infected at least once in their first 2 years of life.

RSV is a leading cause of lower respiratory tract disease hospitalisation in infants aged <12 months. Why | Respiratory syncytial virus (RSV) | The Australian Immunisation Handbook

The RSV Maternal and Infant Protection Program (RSV-MIPP) commenced 3rd Feb 2025 for eligible pregnant women, infants at birth and young children. RSV-MIPP is a comprehensive approach that includes Abrysvo®, a maternal vaccine and Beyfortus® (nirsevimab), an infant monoclonal antibody.

Maternal Vaccine

RSV vaccine Abrysvo® is recommended for pregnant women to protect their newborn infant. Vaccinating women during pregnancy reduces the risk of severe RSV illness in infants under 6 months of age by around 70%. Respiratory syncytial virus (RSV) FAQs | NCIRS

Maternal vaccination with Abrysvo® is the recommended approach to infant RSV protection. It should be promoted for pregnant women at 28 - 36 weeks gestation (ideally 2 weeks before delivery).

Abrysvo® can be co-administered with whooping cough (dTpa - diphtheria, tetanus and pertussis) and influenza vaccines if required.

Order Abrysvo® vaccine for your clinic on the NIP vaccine order form found under the forms and reporting tab on this website.

Important

  • Abrysvo® is the only RSV vaccine approved for use in pregnant women. Abrysvo® is not registered for use in infants and must not be administered to an infant or child.
  • Arexvy®, another RSV vaccine, is registered for use in adults aged 60 years and over and should not be given to pregnant women.
  • Abrysvo® is also registered for use in individuals 60 years of age and above and is only available in the private market for this age group.

Infant monoclonal antibody

Beyfortus® (nirsevimab) is a monoclonal antibody funded by the NT and is available in maternity and paediatric services only, to eligible infants at birth and young children.

Infants eligible to receive Beyfortus® (nirsevimab) are:

Important

Beyfortus® (nirsevimab) is a monoclonal antibody and is only available in maternity and paediatric services.

Further resources

For more information read:

From January 2025 Meningococcal B vaccine will be available for all children aged 6 weeks to under 2 years of age and adolescents aged 14 – 19 years of age.

If the vaccines are commenced under 12 months of age, 3 doses are required.

For catch-up over 12 months to less than 2 years, 2 doses are required.

For adolescents, 2 doses are required.

The minimal interval between all meningococcal B doses is 8 weeks.

For more information read:

Access the latest information and resources on Influenza and COVID-19 vaccination here.

2024 Influenza vaccine information

2024 COVID-19 vaccine information

Correct vaccine storage and handling is fundamental to effective immunisation programs.

This section contains information for vaccine providers on correct vaccine storage, maintaining vaccines at the recommended temperature range of +2°C and +8°C and what to do in the event of a cold chain breach.

For further information regarding vaccine storage refer to the Australian Government's national vaccine storage guidelines 'Strive for 5'.

A comprehensive guide to assist NT vaccine service providers, health care professionals and administration staff in the safe management of vaccines

Vaccine order form

Use this form when ordering all NIP vaccines for your clinic.

Vaccine wastage form online

Use this form to report all vaccine wastage.

In the event of vaccine wastage due to a Cold Chain Breach, do not discard the vaccines until advised by CDC. Call the Immunisation Program on 08 8922 8315 during business hours to report a Cold Chain Breach.

Adverse event following immunisation form

Adverse events following immunisation refers to any untoward medical occurrence that follows immunisation, whether it is expected or unexpected and regardless of whether it is triggered by the vaccine or coincidentally occurs following its administration.

Refer to the Australian Immunisation Handbook for specific definitions and advice on adverse events following immunisation (AEFI’s) or call the Immunisation Program on 08 8922 8315 during business hours.

To report an AEFI on line or to access a hard copy, fill in these forms:

Vaccination recording form

If you are a vaccine provider and do not currently record immunisations electronically, complete this form for people of any age who have received a vaccination.

Email the completed form to ImmunisationUnit.THS@nt.gov.au or fax the form to NT Immunisation on 08 8922 8897.

Rabies/Lyssavirus post-exposure prophylaxis form

Use this form for all cases requiring rabies/lyssavirus post-exposure prophylaxis.

This includes giving rabies immunoglobulin (HRIG) and/or rabies vaccine.

Email completed form to ImmunisationProgram.TEHS@nt.gov.au.

Links to resources

Vaccine administration

Anaphylaxis

Vaccines for Health, Age, Lifestyle and Occupation

Vaccines for specific diseases

Immunisation updates include the latest information on vaccines and schedules for vaccine providers.

The Immunisation Scheduled Substance Treatment Protocol (SSTP) for Nurses, Midwives and Aboriginal and Torres Strait Islander Health Practitioners PDF (273.0 KB) enables vaccine accredited practitioners to legally administer listed vaccines without a doctor’s order or prescription.

All health professionals administering vaccines from this protocol must have completed and hold a current qualification as detailed  in the protocol.

The SSTP for Mpox can be found on the Medicines and poisons notices

Vaccine supply and management framework

This framework applies to all Vaccine Service Providers receiving vaccines from Northern Territory (NT) Health for the purpose of vaccination within the NT.

HESA accredited vaccine courses

To administer vaccines without the order of a medical practitioner in the Northern Territory, nurses, midwives and Aboriginal and Torres Strait Islander Health Practitioners are required to have completed a Health Education Services Australia (HESA) approved vaccine course.

Access HESA approved courses, go to the Health Education Services Australia website.

Maintaining competency

All nurses, midwives and ATSIHP must maintain ongoing professional competency in the delivery of vaccines. This can include formal education modules, seminars, self-directed learning and peer-peer training. Clinicians should be guided by their national board’s guidance on CPD.

One option to maintain competency is that all vaccine providers complete the free About Giving Vaccines Upskill course annually.

To register and complete the course annually, go to the NT Remote Locum Program elearning website.

Give feedback about this page.

Share this page:

URL copied!
Related information